Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers
Glioblastoma, Malignant Glioma, WHO Grade III Glioma
About this trial
This is an interventional supportive care trial for Glioblastoma
Eligibility Criteria
Inclusion Criteria:
- Adults with pathology confirmed high grade glioma, graded as World Health Organization (WHO) grade III and IV
- Ability to use a tablet
- Able to adhere to completing surveys at study visits
- English speaking
- Has a caregiver that has provided oral consent to participate in this study
- Insurance accepted at Mayo Clinic Arizona
Exclusion Criteria:
- Inability to use a tablet
- Inability to adhere to completing surveys at monthly visits
- Unable to speak English
- Lack of a caregiver
- Insurance not accepted at Mayo Clinic Arizona
Sites / Locations
- Mayo Clinic in Arizona
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Group A (visit with neuro-oncologist)
Group B (visit with neuro-oncologist and palliative care team)
Group C (visit with neuro-oncologist, palliative care team)
Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months to address concerns that are identified via the survey and the domain of concern identified by patient and caregiver.
Patients and primary caregiver complete the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist and palliative care team monthly for 6 months to address concerns that are identified by the survey and domains of concerns. Caregivers also attend support sessions led by a social worker monthly for 6 months.
Patients and primary caregiver complete quality of life portion of the BEACON PROQOL survey before each visit. Patients then receive standard of care for high grade glioma consisting of visits with neuro-oncologist monthly for 6 months and address important concerns that come up on the survey. Patients may also receive palliative care consultation as deemed appropriate by the neuro-oncologist.